In:
Small, Wiley, Vol. 19, No. 2 ( 2023-01)
Abstract:
Mono‐chemotherapy has significant side effects and unsatisfactory efficacy, limiting its clinical application. Therefore, a combination of multiple treatments is becoming more common in oncotherapy. Chemotherapy combined with the induction of ferroptosis is a potential new oncotherapy. Furthermore, polymeric nanoparticles (NPs) can improve the antitumor efficacy and decrease the toxicity of drugs. Herein, a polymeric NP, mPEG ‐b‐ PPLGFc@Dox, is synthesized to decrease the toxicity of doxorubicin (Dox) and enhance the efficacy of chemotherapy by combining it with the induction of ferroptosis. First, mPEG ‐b‐ PPLGFc@Dox is oxidized by endogenous H 2 O 2 and releases Dox, which leads to an increase of H 2 O 2 by breaking the redox balance. The Fe(II) group of ferrocene converts H 2 O 2 into ·OH, inducing subsequent ferroptosis. Furthermore, glutathione peroxidase 4, a biomarker of ferroptosis, is suppressed and the lipid peroxidation level is elevated in cells incubated with mPEG ‐b‐ PPLGFc@Dox compared to those treated with Dox alone, indicating ferroptosis induction by mPEG ‐b‐ PPLGFc@Dox. In vivo, the antitumor efficacy of mPEG ‐b‐ PPLGFc@Dox is higher than that of free Dox. Moreover, the loss of body weight in mice treated mPEG ‐b‐ PPLGFc@Dox is lower than in those treated with free Dox, indicating that mPEG ‐b‐ PPLGFc@Dox is less toxic than free Dox. In conclusion, mPEG ‐b‐ PPLGFc@Dox not only has higher antitumor efficacy but it reduces the damage to normal tissue.
Type of Medium:
Online Resource
ISSN:
1613-6810
,
1613-6829
DOI:
10.1002/smll.202205024
Language:
English
Publisher:
Wiley
Publication Date:
2023
detail.hit.zdb_id:
2168935-0
Permalink